- Home
- MCRB vs IGMS Comparison
MCRB vs IGMS Comparison
Compare MCRB & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- IGMS
- Stock Information
- Founded
- MCRB 2010
- IGMS 1993
- Country
- MCRB United States
- IGMS United States
- Employees
- MCRB N/A
- IGMS N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- IGMS Health Care
- Exchange
- MCRB Nasdaq
- IGMS Nasdaq
- Market Cap
- MCRB 81.2M
- IGMS 82.1M
- IPO Year
- MCRB 2015
- IGMS 2019
- Fundamental
- Price
- MCRB $7.06
- IGMS $1.13
- Analyst Decision
- MCRB Hold
- IGMS Hold
- Analyst Count
- MCRB 5
- IGMS 8
- Target Price
- MCRB $73.67
- IGMS $6.14
- AVG Volume (30 Days)
- MCRB 146.8K
- IGMS 152.8K
- Earning Date
- MCRB 05-07-2025
- IGMS 05-20-2025
- Dividend Yield
- MCRB N/A
- IGMS N/A
- EPS Growth
- MCRB N/A
- IGMS N/A
- EPS
- MCRB 0.03
- IGMS N/A
- Revenue
- MCRB N/A
- IGMS $2,679,000.00
- Revenue This Year
- MCRB N/A
- IGMS $121.76
- Revenue Next Year
- MCRB N/A
- IGMS $46.83
- P/E Ratio
- MCRB $213.09
- IGMS N/A
- Revenue Growth
- MCRB N/A
- IGMS 25.77
- 52 Week Low
- MCRB $7.18
- IGMS $0.92
- 52 Week High
- MCRB $30.60
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- MCRB 33.07
- IGMS 39.53
- Support Level
- MCRB $8.92
- IGMS $1.11
- Resistance Level
- MCRB $9.97
- IGMS $1.22
- Average True Range (ATR)
- MCRB 1.08
- IGMS 0.11
- MACD
- MCRB -0.06
- IGMS -0.02
- Stochastic Oscillator
- MCRB 10.61
- IGMS 5.56
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.